Residency · Portland, OR
Sponsored by Oregon Health & Science University (OHSU Health)
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2021 · 510 citations · Erik Mittra
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023 · 106 citations · Erik Mittra
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
JCO oncology practice · 2026 · 19 citations · Erik Mittra
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
CA: a cancer journal for clinicians · 2024 · 72 citations · Erik Mittra
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 96 citations · Erik Mittra
Safety of Large Language Models in Addressing Depression.
Cureus · 2023 · 44 citations ·
Skull Base Osteomyelitis: A Comprehensive Imaging Review.
AJNR. American journal of neuroradiology · 2021 · 64 citations · Gagandeep Choudhary
Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025 · 22 citations · Erik Mittra